[Federal Register Volume 90, Number 48 (Thursday, March 13, 2025)]
[Notices]
[Pages 11990-11991]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2025-04029]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2024-N-3314]
Alnashir Alibhai Punjani: Final Debarment Order
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or the Agency) is
issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C
Act) debarring Alnashir Alibhai Punjani for a period of 5 years from
importing or offering for import any drug into the United States. FDA
bases this order on a finding that Mr. Punjani was convicted of one
felony count under Federal law for conspiracy to deliver and introduce
unapproved drugs. The factual basis supporting Mr. Punjani's
conviction, as described below, is conduct relating to the importation
into the United States of a drug or controlled substance. Mr. Punjani
was given notice of the proposed debarment and was given an opportunity
to request a hearing to show why he should not be debarred. As of
November 10, 2024 (30 days after receipt of the notice), Mr. Punjani
had not responded. Mr. Punjani's failure to respond and request a
hearing constitutes a waiver of his right to a hearing concerning this
matter.
DATES: This order is applicable March 13, 2025.
ADDRESSES: Any application by Mr. Punjani for termination of debarment
under section 306(d)(1) of the FD&C Act (21 U.S.C. 335a(d)(1)) may be
submitted at any time as follows:
Electronic Submissions
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. An application
submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because
your application will be made public, you are solely responsible for
ensuring that your application does not include any confidential
information that you or a third party may not wish to be posted, such
as medical information, your or anyone else's Social Security number,
or confidential business information, such as a manufacturing process.
Please note that if you include your name, contact information, or
other information that identifies you in the body of your application,
that information will be posted on https://www.regulations.gov.
If you want to submit an application with confidential
information that you do not wish to be made available to the public,
submit the application as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For a written/paper application submitted to the Dockets
Management Staff, FDA will post your application, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All applications must include the Docket No. FDA-
2024-N-3314. Received applications will be placed in the docket and,
except for those submitted as ``Confidential Submissions,'' publicly
viewable at https://www.regulations.gov or at the Dockets Management
Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.
[[Page 11991]]
Confidential Submissions--To submit an application with
confidential information that you do not wish to be made publicly
available, submit your application only as a written/paper submission.
You should submit two copies total. One copy will include the
information you claim to be confidential with a heading or cover note
that states ``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The
Agency will review this copy, including the claimed confidential
information, in its consideration of your application. The second copy,
which will have the claimed confidential information redacted/blacked
out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management
Staff. Any information marked as ``confidential'' will not be disclosed
except in accordance with 21 CFR 10.20 and other applicable disclosure
law. For more information about FDA's posting of comments to public
dockets, see 80 FR 56469, September 18, 2015, or access the information
at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket, go to https://www.regulations.gov
and insert the docket number, found in brackets in the heading of this
document, into the ``Search'' box and follow the prompts and/or go to
the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville,
MD 20852 between 9 a.m. and 4 p.m., Monday through Friday, 240-402-
7500. Publicly available submissions may be seen in the docket.
FOR FURTHER INFORMATION CONTACT: Jaime Espinosa, Division of Compliance
and Enforcement, Office of Policy, Compliance, and Enforcement, Office
of Regulatory Affairs, Food and Drug Administration, 240-402-8743, or
[email protected].
SUPPLEMENTARY INFORMATION:
I. Background
Section 306(b)(1)(D) of the FD&C Act permits debarment of an
individual from importing or offering for import any drug into the
United States if FDA finds, as required by section 306(b)(3)(C) of the
FD&C Act, that the individual has been convicted of a felony for
conduct relating to the importation into the United States of any drug
or controlled substance.
On June 18, 2024, Mr. Punjani was convicted, as defined in section
306(l)(1) of the FD&C Act, in the U.S. District Court for Northern
District of Georgia-Atlanta Division, when the court accepted his plea
of guilty and entered judgment against him for the offense of
conspiracy to deliver and introduce unapproved drugs in violation of 18
U.S.C. 371 and 21 U.S.C. 331(c) and 333(a)(2) (sections 301(c) and
303(a)(2) of the FD&C Act). The underlying facts supporting the
conviction are as follows:
As contained in the information, filed on January 18, 2024, in or
about March 2019, and continuing until in or about September 2022, Mr.
Punjani imported thousands of AUROGRA 100 mg tablets, VIGORE 100 mg
tablets, and CENFORCE 100 mg tablets, which were male enhancement pills
manufactured in India, but not authorized for sale in the United States
by FDA. These pills contained the active pharmaceutical ingredient
(API) sildenafil. Sildenafil is the same API used in the prescription
drug VIAGRA. The FDA approved drugs containing the active ingredient
sildenafil are only available by prescription and may cause serious
side effects for those suffering from cardiovascular disease,
hypertension, bleeding disorders, and other related health conditions.
The drugs Mr. Punjani imported and resold had not been approved by FDA
meaning that they did not have the same assurance of safety or efficacy
as FDA approved drugs. Per the information, Mr. Punjani used commercial
shippers to ship the tablets from India to multiple locations in
Georgia where he, with the intent to defraud and mislead, organized
them for resell in the state of Georgia. The labeling on the drugs Mr.
Punjani resold did not contain adequate directions for use.
FDA sent Mr. Punjani, by certified mail, on September 26, 2024, a
notice proposing to debar him for a 5-year period from importing or
offering for import any drug into the United States. The proposal was
based on a finding under section 306(b)(3)(C) of the FD&C Act that Mr.
Punjani's felony conviction under Federal law for conspiracy to deliver
and introduce unapproved drugs in violation of 18 U.S.C. 371 and
sections 301(c) and 303(a)(2) of the FD&C Act, was for conduct relating
to the importation into the United States of any drug or controlled
substance into the United States because Mr. Punjani illegally imported
and introduced unapproved and misbranded prescription drug products
into interstate commerce in the United States. In proposing a debarment
period, FDA weighed the considerations set forth in section 306(c)(3)
of the FD&C Act that it considered applicable to Mr. Punjani's offense
and concluded that the offense warranted the imposition of a 5-year
period of debarment.
The proposal informed Mr. Punjani of the proposed debarment and
offered him an opportunity to request a hearing, providing him 30 days
from the date of receipt of the letter in which to file the request,
and advised him that failure to request a hearing constituted a waiver
of the opportunity for a hearing and of any contentions concerning this
action. Mr. Punjani received the proposal and notice of opportunity for
a hearing on October 11, 2024. Mr. Punjani failed to request a hearing
within the timeframe prescribed by regulation and has, therefore,
waived his opportunity for a hearing and waived any contentions
concerning his debarment (21 CFR part 12).
II. Findings and Order
Therefore, the Division of Field Enforcement Director, Office of
Inspections and Investigations, under section 306(b)(3)(C) of the FD&C
Act, under authority delegated to the Director, Division of
Enforcement, finds that Mr. Alnashir Alibhai Punjani has been convicted
of a felony under Federal law for conduct relating to the importation
into the United States of any drug or controlled substance. FDA finds
that the offense should be accorded a debarment period of 5 years as
provided by section 306(c)(2)(A)(iii) of the FD&C Act.
As a result of the foregoing finding, Mr. Punjani is debarred for a
period of 5 years from importing or offering for import any drug into
the United States, effective (see DATES). Pursuant to section 301(cc)
of the FD&C Act, the importing or offering for import into the United
States of any drug by, with the assistance of, or at the direction of
Mr. Punjani is a prohibited act.
Dated: March 7, 2025.
P. Ritu Nalubola,
Associate Commissioner for Policy.
[FR Doc. 2025-04029 Filed 3-12-25; 8:45 am]
BILLING CODE 4164-01-P